Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT06213857 Sponsor: Tanta University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT06213857
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old, of any sex
  • People whose kidneys and liver are working normally
  • People who are willing to sign a consent form agreeing to take part in the study
  • People who have been diagnosed with Ulcerative Colitis (a condition that causes inflammation in the large intestine) confirmed by a colonoscopy, lab tests, and tissue samples, following established medical guidelines

Who may not be able to join:

  • People who have previously had an allergic or severe allergic reaction to silymarin (a natural substance found in milk thistle)
  • People with significant kidney or liver problems
  • People who do not wish to participate in the study
  • Women who are pregnant, breastfeeding, or people who smoke
  • People who are currently taking steroid medications (such as prednisolone) or biological therapy (specialist treatments that target the immune system)
  • People who are currently taking any other antioxidant supplements or medications
  • People who have other illnesses where damage caused by harmful molecules in the body plays a role, such as chronic liver disease or lung infections (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sahar M Ghobashy ElHaggar, Professor, Tanta University

Phone: +201140399467

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
1 May 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

2 points or more decrease in the Mayo score from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov